Dr. Joseph Varon, of Houston’s United Memorial Medical Center, and a team of researchers/physicians/ICU Specialists who have been working on COVID-19 patients, held a press conference last week regarding the treatment and even prevention of COVID-19 through a protocol developed through their own research.
According to Varon, one medication that has been effective in treating COVID-19 is Ivermectin. This drug has been around for over 40 years to treat parasitic infections and it’s affordable. Varon states that Ivermectin has been used as part of the I-MASK protocol to treat patients who are post-exposure, early stage, and even late stage, with some success and safety. A major find is that the drug is also preventative. The drug is not only anti-viral, but also anti-inflammatory.
The press conference was more of a call to action to request medical authorities at the federal and global level to study and authorize this treatment, and to update protocols of treatment, which has not occurred since August, 2020. In fact, it was in August that the FDA authorized Ivermectin for clinical trials. With the data already collected, they feel it is time to update the treatment protocols.
According to Dr. Pierre Kory of St. Luke’s in Wisconsin, multiple studies have shown decreases in mortality and positive treatment outcomes. As a prophylactic, it has been successful in preventing COVID-19. He states that lives are being saved.
Dr. Varon stated at various points that the group of physicians are in no way affiliated with the drug companies and that they have no conflicts of interest in supporting this method of treating and preventing COVID-19.
Professor of Medicine Dr. Paul Marik offered a global call to action for health authorities to look at the clinical trial data on Ivermectin, validate the data, and push for its use as we reach a critical point in the pandemic in which better treatments are needed. Marik stated quite emotively, “We must act now, we must act with conviction, and we must act with compassion.” Federal leadership has so far ignored the request.
Dr. Marik also pointed to clinical outcomes and benefits of various medications utilized and debated about, including Hydrocloroquine, Remdesivir, and others. They found that only Ivermectin had benefits for pre-exposure, post-exposure, and pulmonary/inflammatory/hospitalization phases of COVID-19.
Dr. Varon added that medical providers are tired of the death and destruction by COVID-19 and they have developed this treatment to not only help patients, but to help medical providers. When asked regarding competition with the billions of dollars already invested in vaccine development, Varon offered a dose of reality: 60% of the world will need to be vaccinated to reach some level of immunity and he has heard from his own patients and others that they are not willing or trusting of the vaccine enough to take it. What FLCCC offers is an alternative, as well as a way proven through their own research, to address COVID-19 now to compliment the vaccination process. As Dr, Marik put it, “It’s not a competition.”
Watch the press conference here, which includes Q&A with media for more information. One can also go to the FLCCC website to read the studies and other pertinent information. Here is the press kit that was also provided.